Navigation Links
Auxilium Pharmaceuticals, Inc. Announces Fourth Quarter and Full Year 2012 Financial Results and Guidance for 2013
Date:2/26/2013

l position, future revenues, projected costs, prospects, plans and objectives of management and other statements regarding matters that are not historical facts, and involve predictions. These statements involve known and unknown risks, uncertainties and other factors that may cause actual results, performance, achievements or prospects to be materially different from any future results, performance, achievements or prospects expressed in or implied by such forward-looking statements. In some cases you can identify forward-looking statements by terminology such as ''may'', ''will'', ''should'', ''would'', ''expect'', ''intend'', ''plan'', ''anticipate'', ''believe'', ''estimate'', ''predict'', ''potential'', ''seem'', ''seek'', ''future'', ''continue'', or ''appear'' or the negative of these terms or similar expressions, although not all forward-looking statements contain these identifying words.  No specific assurances can be given with respect to whether we will: continue to be a profitable and sustainable biopharmaceutical company; execute successfully on our commercial or development plans; obtain FDA approval in our expected timeframe, or at all, and successfully launch XIAFLEX for the treatment of Peyronie's; develop XIAFLEX for the treatment of multiple potential indications; provide non-GAAP financial measures that will be useful for investors; or achieve 2013 financial results consistent with the guidance we have provided.  Although forward-looking statements are based on Auxilium's current plans or assessments that are believed to be reasonable as of the date of this press release, they inherently involve certain risks and uncertainties. These forward-looking statements are subject to a number of risks and uncertainties, including those discussed under ''Risk Factors'' in Auxilium's Annual Report on Form 10-K for the year ended December 31, 2012, filed with the Securities and Exchange Commission (the "SEC") on February 26, 2013. While Auxilium ma
'/>"/>
SOURCE Auxilium Pharmaceuticals, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14

Related biology technology :

1. Auxilium Announces Appointments to Enhance Leadership Team
2. Auxilium Pharmaceuticals, Inc. to Present at the Jefferies 2012 Global Healthcare Conference
3. Auxilium Pharmaceuticals, Inc. to Present At The JMP Securities 2012 Healthcare Conference
4. Auxilium Pharmaceuticals, Inc. to Present at the Canaccord Genuity 32nd Annual Growth Conference
5. Auxilium Pharmaceuticals, Inc. to Present At The Oppenheimer 23rd Annual Growth Conference
6. Auxilium Pharmaceuticals to Announce Fourth Quarter and Full Year 2012 Results and Conduct Conference Call on Tuesday, February 26, 2013
7. Auxilium Pharmaceuticals, Inc. to Present at the Leerink Swann Global Healthcare Conference
8. Keryx Biopharmaceuticals, Inc. Announces Upcoming Poster Presentations of Zerenex™ (Ferric Citrate) at the Upcoming American Society of Nephrology Kidney Week 2011 Annual Meeting
9. Synergy Pharmaceuticals, Inc. Files Suit Against Ironwood Pharmaceuticals, Inc. and its Chief Scientific Officer and Senior VP of R&D, Dr. Mark G. Currie
10. Silence Therapeutics Partner, Quark Pharmaceuticals, Extends its Agreement With Pfizer to Develop one of Its Compounds Containing Silences AtuRNAi in a New Indication
11. MAP Pharmaceuticals, Inc. Announces Proposed Public Offering of Common Stock
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/27/2015)... 27, 2015 HUYA Bioscience International (HUYA) today announced ... Japan Society of HTLV-1, held this week at the ... of the Society is to promote research on HTLV-1 ... medical technology and research related to these fields to ... "HUYA is proud to support this prestigious conference," said ...
(Date:8/27/2015)... Switzerland (PRWEB) , ... August 27, 2015 , ... ... on customers’ weighing needs and expertly narrows down the product choices to a ... selection criteria pares down the list to models that fit best with the ...
(Date:8/26/2015)... ... August 26, 2015 , ... ... today that a second US laboratory is to open in Manhattan, Kansas in ... continued partnership and long-term growth of research and development through collaboration with researchers ...
(Date:8/26/2015)... ... 26, 2015 , ... Lee Biosolutions, a global biotech healthcare ... of highly valued cardiac markers used in early detection of heart disease due ... has led to the development and commercialization of important cardiac biomarkers used in ...
Breaking Biology Technology:HUYA Bioscience International Sponsors Japan Society Of HTLV-1 Annual Meeting 2HUYA Bioscience International Sponsors Japan Society Of HTLV-1 Annual Meeting 3HUYA Bioscience International Sponsors Japan Society Of HTLV-1 Annual Meeting 4METTLER TOLEDO Updates Online Scale Selection Tool 2MediVet Biologics Animal Health Secures Additional Laboratory Facility in Manhattan, Kansas 2MediVet Biologics Animal Health Secures Additional Laboratory Facility in Manhattan, Kansas 3Lee Biosolutions Announces Increased Investment in the Development and Manufacturing of Biomarkers Used in Early Detection Of Heart Disease 2
... /PRNewswire/ - Trillium Therapeutics Inc. (TTI), a biopharmaceutical company developing ... two definitive license agreements with University Health Network (UHN) and ... , granting Trillium exclusive worldwide rights to commercialize two immunology ... cancer. , ...
... of animals and plants is the most important technological ... species has occurred as humans have used individuals carrying ... issue of Nature an international team led ... the secrets underlying the remarkable development of the domestic ...
... ... ... , ... , , , , ...
Cached Biology Technology:Trillium expands immunology pipeline and enters stem cell field through in-licensing of two new programs 2Trillium expands immunology pipeline and enters stem cell field through in-licensing of two new programs 3Scientific breakthrough in genetic studies of animal domestication 2Toxikon Corporation Hosts Extractables and Leachables Spring Seminar 2Toxikon Corporation Hosts Extractables and Leachables Spring Seminar 3
(Date:8/4/2015)... , Aug. 04, 2015 ... ) has announced the addition of the ... Software, and Service), Sub-Segment (Computer Forensics, Network ... Tool Types, Service, Vertical and Region - ... their offering. By Component (Hardware, ...
(Date:8/3/2015)... 2015 Synaptics, Inc. (Nasdaq: SYNA ), ... that members of the executive management team will present ... Technology Leadership Forum on Tuesday, August 11, 2015 at ... at the Sonnenalp Resort in Vail, CO. ... forward-looking information. An audio webcast of the event will ...
(Date:7/31/2015)... SHENZHEN, China , 31 de julio de 2015 ... sobre Genómica (ICG-10,  www.icg-10.org ) del 22 al 25 ... . La conferencia celebra su décimo ... se ha convertido en una de las reuniones anuales ... ,ómicas, y es una de las conferencias científicas más ...
Breaking Biology News(10 mins):Digital Forensics Market - The Market Represents a Compound Annual Growth Rate (CAGR) of 11.3% From 2015 to 2020 2La 10ª Conferencia Internacional sobre Genómica (ICG-10) comienza en octubre 2La 10ª Conferencia Internacional sobre Genómica (ICG-10) comienza en octubre 3
... Genetic parasites invaded the mammalian genome more than 100 million ... transforming the uterus in the ancestors of humans and other ... for developing young, a new Yale University study has found. ... Nature Genetics describe in unprecedented detail the molecular ...
... modified (GM) food are threatening public acceptance of the ... also hampering Europe,s response to the global challenge of ... claim. Drawing upon a decade of evidence, researchers ... that Europe,s regulation of GM crops has become less ...
... a $3.33 million award from the Wallace H. Coulter ... solutions to benefit patients. The five-year Coulter Translational ... outcomes to save, extend and improve patients, lives. With ... a $1 million operating budget for each of the ...
Cached Biology News:Invasion of genomic parasites triggered modern mammalian pregnancy 2
Immunogen: Synthetic peptide (aa sequence is considered to be commercially sensitive) Storage: -20 C, Avoid Freeze/Thaw Cycles...
... Immunogen: Fusion protein derived from ... ASIP/PAR-3 (atypical PKC isotype-specific interacting protein/ ... not related to the protease-activated-receptors also ... Xenopus (positive controls: Caco-2 MDCK A6 ...
... C-1-tetrahydrofolate synthase, ... [Includes: Methylenetetrahydrofolate dehydrogenase ... cyclohydrolase (EC 3.5.4.9); ... 6.3.4.3)]. [Source:Uniprot/SWISSPROT;Acc:P11586] ...
...
Biology Products: